

LEVOPLANT

Subdermal contraceptive implant

Levoplant™ is a WHO Prequalified subdermal contraceptive implant effective for up to 3 years. It is a safe, highly convenient and acceptable method of contraception.



CHARACTERISTICS



High quality¹, affordable, contraceptive implant that is composed of two thin and flexible silicone rods



WHO prequalified contraceptive implant²



Contains 75 mg of levonorgestrel in each rod (150 mg total)



60 month (five year) shelf life

EFFICACY

- More than 99% effective in a 3 year period – less than 1 pregnancy per 100 women over duration of use²

*For heavier women, the effectiveness of Levoplant™ may decrease near the end of the duration. Earlier replacement can be discussed.

MECHANISM OF ACTION

- Prevents the release of the egg
- Thickens mucus in the cervical canal to prevent sperm reaching and fertilizing the egg

ADMINISTRATION

- Inserted just under the skin of a woman's upper arm by a trained healthcare provider using a disposable trocar
- Simple insertion and removal takes a few minutes in the clinical setting with local anaesthetic

BENEFITS

- Estrogen free: avoids estrogen-related side effects that may be experienced with combined hormonal contraceptive methods
- Action to prevent pregnancy is not required once the implant is inserted.
- The implant can be removed at any time at the woman's request and there is no delay in return to fertility
- Almost all women of any age, including those who have just given birth, are breastfeeding, or women who have had an abortion can use Levoplant™*
*if they are medically eligible



SIDE EFFECTS

Irregular bleeding patterns may occur but are not harmful. Abdominal pain, weight changes, breast tenderness, mood changes, migraine can also be experienced.

CONTRAINDICATIONS

Unexplained vaginal bleeding, severe liver cirrhosis or liver tumor, history of breast cancer or current deep blood clots.

1. Steiner MJ, et al. Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two-rod contraceptive implant over 4 years in the Dominican Republic. *Contracept X*. (2019) 1:100006.
2. World Health Organization Department of Sexual and Reproductive Health and Research (WHO/SRH) and Johns Hopkins Bloomberg School of Public Health/ Center for Communication Programs (CCP), Knowledge SUCCESS. *Family Planning: A Global Handbook for Providers* 4th edition, 2022.